Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Antiplatelet Treatment in Stroke: New Insights

Author(s): Haralampos Milionis, Angelos Liontos, Kostantinos Vemmos and Konstantinos Spengos

Volume 22, Issue 29, 2016

Page: [4617 - 4626] Pages: 10

DOI: 10.2174/1381612822666160610100624

Price: $65

Abstract

Background: Stroke is a feared vascular event among healthy people and those with cardiovascular disease, and holds a leading position as a cause of disability and death worldwide. Antiplatelet therapy is central in the management of patients with ischemic nonembolic stroke and transient ischemic attacks. Methods: In this narrative review, we provide an overview and update of evidence regarding antiplatelet treatment in the primary and secondary prevention of stroke. Results: Aspirin, clopidogrel and aspirin plus dipyridamole are the mainstays of antiplatelet treatment post-stroke, while promising agents include triflusal, cilostazol and ticagrelor. Available data are in favor of dual antiplatelet treatment in the early treatment of atherosclerotic large vessel disease. Long-term dual antiplatelet treatment should be individualized keeping in mind the higher rates of bleeding complications. Conclusion: Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke or transient ischemic attack. Moreover, clinicians should carefully assess the pros and cons in each case and individualize the need for prolonged dual antiplatelet therapy.

Keywords: Antiplatelet treatment, dual therapy, ischemic stroke, transient ischemic attack, prevention, recurrence.

« Previous

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy